<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276558</url>
  </required_header>
  <id_info>
    <org_study_id>REC0559-B-001</org_study_id>
    <nct_id>NCT04276558</nct_id>
  </id_info>
  <brief_title>REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients</brief_title>
  <official_title>Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recordati Rare Diseases</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Recordati Rare Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559&#xD;
      in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of&#xD;
      America.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will have an initial period of dose escalation followed by a parallel recruitment period. Randomisation in the first 24 patients will be sequential and after, patients will be randomised to all 4 treatment arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-masked: dose and nature of the product</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal healing</measure>
    <time_frame>At week 8</time_frame>
    <description>The primary endpoint of this study is the percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>At week 8</time_frame>
    <description>• Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Neurotrophic Keratitis</condition>
  <arm_group>
    <arm_group_label>Dose 1 - 0.5 µg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 - 2.5 µg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 - 5 µg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udonitrectag</intervention_name>
    <description>Eye drop solution in single dose unit.</description>
    <arm_group_label>Dose 1 - 0.5 µg/day</arm_group_label>
    <arm_group_label>Dose 2 - 2.5 µg/day</arm_group_label>
    <arm_group_label>Dose 3 - 5 µg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Eye drop solution with no active substance in single dose unit.</description>
    <arm_group_label>Dose 1 - 0.5 µg/day</arm_group_label>
    <arm_group_label>Dose 2 - 2.5 µg/day</arm_group_label>
    <arm_group_label>Dose 3 - 5 µg/day</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have read, understood, and signed the informed consent form (ICF).&#xD;
&#xD;
          2. Be a male or female aged ≥18 years at the time of ICF signature.&#xD;
&#xD;
          3. Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye&#xD;
             (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow&#xD;
             eye can be enrolled.&#xD;
&#xD;
             for the study eye&#xD;
&#xD;
          4. Have no objective clinical evidence of improvement in the PED or corneal ulceration&#xD;
             within the 2 weeks before the screening visit despite use of conventional non-surgical&#xD;
             treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral&#xD;
             doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined&#xD;
             by the investigator's or referring physician's medical record.&#xD;
&#xD;
          5. Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer)&#xD;
             within the area of the PED or corneal ulcer and outside of the area of the defect in&#xD;
             at least one corneal quadrant.&#xD;
&#xD;
          6. Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have participated in any clinical trial with an investigational drug/device within 2&#xD;
             months before the Screening Visit and throughout the study duration.&#xD;
&#xD;
          2. Have a known hypersensitivity to one of the components of the study drug or procedural&#xD;
             medications (eg, fluorescein), including to a compound chemically related to MT8&#xD;
&#xD;
          3. Have a presence or history of any ocular or systemic disorder or condition that might&#xD;
             hinder the efficacy of the study treatment or its evaluation, could possibly interfere&#xD;
             with the interpretation of study results, or could be judged by the investigator to be&#xD;
             incompatible with the study visit schedule or conduct (eg, progressive or degenerative&#xD;
             corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly&#xD;
             controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or&#xD;
             that may compromise the safety of the patient.&#xD;
&#xD;
          4. Have a significant history of alcohol abuse or drug/solvent abuse&#xD;
&#xD;
          5. Be unwilling to comply with any study assessments or procedures.&#xD;
&#xD;
          6. Be a woman who is pregnant, nursing or planning a pregnancy.&#xD;
&#xD;
          7. Be a woman of childbearing potential not using a highly effective method of birth&#xD;
             control.&#xD;
&#xD;
          8. Be a male patient who is not permanently sterile and who is not willing to use condoms&#xD;
             during the study and for 4 weeks after the end of study treatment.&#xD;
&#xD;
             For the study eye:&#xD;
&#xD;
          9. Have any active ocular infection (bacterial, viral, fungal or protozoal) or active&#xD;
             inflammation not related to NK in the study eye.&#xD;
&#xD;
         10. Have any other ocular disease requiring topical ocular treatment in the study eye&#xD;
             during the course of the study treatment period, except for glaucoma if treated by&#xD;
             preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks&#xD;
             before screening and during the study),&#xD;
&#xD;
         11. Receive topical ophthalmological treatments other than the study drug provided by the&#xD;
             study Sponsor and the treatments allowed by the study protocol (eg, preservative-free&#xD;
             artificial tears; preservative-free eye drop (single-agent treatment, once daily,&#xD;
             stable regimen 4 weeks before screening and during the study) for glaucoma; topical&#xD;
             antibiotics; other than tetracycline).&#xD;
&#xD;
         12. Have severe blepharitis and/or severe meibomian gland disease in the study eye.&#xD;
&#xD;
         13. Have severe vision loss in the study eye with no potential for visual improvement in&#xD;
             the opinion of the investigator as a result of the study treatment.&#xD;
&#xD;
         14. Have evidence of corneal ulceration/melting involving the posterior third of the&#xD;
             corneal stroma, or perforation in the study eye.&#xD;
&#xD;
         15. Have a history of any ocular surgery (including laser or refractive surgical&#xD;
             procedures) within 3 months before the Screening Visit in the study eye. An exception&#xD;
             to the preceding statement will be allowed if the ocular surgery is considered to be&#xD;
             the cause of the Stage 2 or 3 NK.&#xD;
&#xD;
         16. Have a history of corneal transplantation in the study eye, except if performed to&#xD;
             treat NK and at least 6 months prior screening.&#xD;
&#xD;
         17. Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy,&#xD;
             conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has&#xD;
             disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after&#xD;
             the procedure) in the study eye.&#xD;
&#xD;
         18. Use therapeutic contact lenses or wear contact lenses for refractive correction during&#xD;
             the study treatment periods in the eye(s) with NK.&#xD;
&#xD;
         19. Have an anticipated need for punctal occlusion during the study treatment period.&#xD;
             Patients with punctal occlusion or punctal plugs inserted before the study are&#xD;
             eligible for enrolment provided that the punctal occlusion is maintained during the&#xD;
             study.&#xD;
&#xD;
         20. Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from&#xD;
             glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or&#xD;
             during the study are not eligible, except if the ophthalmic drops is a&#xD;
             preservative-free treatment administered maximum once daily as a single-agent&#xD;
             treatment and at a stable regimen 4 weeks before screening and at the same dose during&#xD;
             the study. Patients treated with oral intraocular pressure-lowering drugs at the&#xD;
             Screening Visit and during the study may be enrolled if their glaucoma status is&#xD;
             assessed as stable and controlled.&#xD;
&#xD;
             For the fellow eye&#xD;
&#xD;
         21. Have Stage 2 or 3 NK or perforation.&#xD;
&#xD;
             For any eye:&#xD;
&#xD;
         22. Have a history of ocular cancer.&#xD;
&#xD;
         23. Have had prior treatment with Oxervate™&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Béatrice Martin, PhD</last_name>
    <phone>+33147736458</phone>
    <email>martin.be@recordati.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline Plisson, MD</last_name>
    <phone>+33147736458</phone>
    <email>plisson.c@recordati.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429-8722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nature Coast Clinical Research</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bascom Palmer Eye Institute</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine UMSOM</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Maryland School of Medicine UMSOM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silverstein Eye Centers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tennessee Health Science Center (UTHSC) - College of Medicine (COM) - Hamilton Eye Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103-3452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>The University of Tennessee Health Science Center (UTHSC) College of Medicine (COM) - Hamilton Eye Institute</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyos Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toyos Clinic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates HEA - Gramercy Location</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houston Eye Associates HEA Gramercy Location</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hôpital Fondation Adolphe de Rothschild</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hôpital Universitaire Necker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Universitaetsklinikum Frankfurt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saarland University Medical Center</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saarland University Medical Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>nordBLICK Augenklinik Bellevue</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nordBLICK Augenklinik Bellevue</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Dept. of Ophthalmology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Semmelweis University Dept. of Ophthalmology</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pecs - Dpt of Ophthalmology</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Pecs Dpt of Ophthalmology</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Szeged Department of Ophthalmology</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Szeged Department of Ophthalmology</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università Magna Grecia di Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Università Magna Grecia di Catanzaro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Marco Hospital</name>
      <address>
        <city>Catania</city>
        <state>Sicily</state>
        <zip>95121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>San Marco Hospital</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Privato</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ospedali Privato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Gaetano Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azienda Ospedaliera Universitaria Policlinico Gaetano Martino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vissum</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vissum Instituto Oftalmologico</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmologia Barraquer</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Centro de Oftalmologia Barraquer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cartuja Vision - Centro de Servicios Oftlamologicos</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cartuja Vision Centro de Servicios Oftlamologicos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital - St Paul's Clinical Eye Research Centre</name>
      <address>
        <city>Liverpool</city>
        <state>Mersey</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Royal Liverpool University Hospital St Paul's Clinical Eye Research Centre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moorfields Eye Hospital NHS Foundation Trust</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

